Surfactant replacement has been shown to be an effective treatment for neonatal respiratory distress syndrome in a number of non-randomised -3 and randomised controlled trials.4-11 The latter trials were designed to prevent respiratory distress syndrome or to treat established disease (intervention studies).4 III Three studies showed reduced mortality in treated babies.5 8 9 and one showed a decreased incidence of intraventricular haemorrhage after prophylaxis with surfactant at birth.5
We report the results of a randomised intervenion study of surfactant replacement in neonatal respiratory distress syndrome, which for the first time shows a decreased incidence of intraventricular haemorrhage in treated babies.
Surfactant
The surfactant was prepared from minced porcine lungs by chloroform-methanol extraction and liquid gel chromatography,'2 and it contains roughly 99% of polar lipids, mainly phospholipids, and 1% of hydrophobic proteins (molecular weight <15 000).
After chromatography the material was dissolved in chloroform and passed through a 0-2 ,um filter. The subsequent steps of the preparation procedure, including evaporation of the chloroform and suspension in saline, were carried out under sterile conditions. Repeated bacterial cultures from the original batch and from the individual phials after the instillation procedure gave negative results. The physiological activity of our surfactant has been documented in experiments on preterm newborn rabbits receiving artificial ventilation. '2 13 Patients and methods Twenty nine preterm infants with birth weights of 700-2000 g were entered in the study. All and A-aDO2. To evaluate the significance of differences when the data are not parametrically distributed we also used Mann-Whitney U tests. The p values quoted in the figures are for independent t tests but we found no changes after Mann-Whitney U tests except for A-aDO2 at five days when the difference between the groups was not significant (p=007). Table 2 shows the changes in ventilator (1978) .15 grade IV; and another control baby from grade II to grade IV.) There were no differences in the incidence of severe intraventricular haemorrhage (grade III or IV) between groups, although the tendency was for the more severe haemorrhages to occur in the control babies. Pneumothorax and intraventricular haemorrhage were associated with each other in controls but not in treated babies (table 4) .
Interstitial infiltrates on chest radiography were found more commonly after surfactant instillation (p=0.039), but bacterial cultures from the airways remained sterile for up to seven days.
There were no differences in duration of mechanical ventilation and oxygen treatment in the two groups (table 3) . Table 5 shows the causes of death in both groups. Only two babies treated with surfactant died of acute respiratory illness; one after pneumothorax and one with persistent fetal circulation that was unresponsive to tolazoline. This baby was of 26 weeks' gestation and the membranes had been ruptured for five weeks before delivery, making a diagnosis of pulmonary hypoplasia likely, but consent for a postmortem examination was not given. One further treated baby died after the first week from Pseudomonas pneumonia and mild 71) 3 (21) 1 (7) 9 (64) 4 (29) 8 (57) 8 (57) 9 (64) 3/11 (27) 194 ( 21 Randomised studies of surfactant replacement have been of two types: preventive where the surfactant is given at birth to very immature babies,5-9 or interventive where surfactant is given only to babies who are very ill with respiratory distress syndrome.4 it)11 Intervention studies have the advantage that all babies entered have respiratory disease, and smaller study numbers may be needed to show beneficial effects. Interventive studies of natural surfactant replacement have shown a reduced incidence of pneumothorax and death or bronchopulmonary dysplasia in treated infants.4 1 1 While there was acute improvement in oxygenation, which lasted from three to six days, there was no reduction in the incidence of intraventricular haemorrhage.4 1 t Only the largest of the preventive studies showed any reduction in intraventricular haemorrhage after treatment.
We found a similar acute improvement in oxygenation which allowed FiO2 to be reduced in babies treated with surfactant. The difference between the groups remained significant for one week despite a potential bias in our data collection: five of the most severely ill control babies died between 3 and 7 days of age. After 24 hours ventilator settings could also be reduced and this may have accounted for the decreased incidence of pneumothorax in treated babies, especially those weighing less than 1200 g. The reduction in intraventricular haemorrhage may have been due to a combination of improved oxygenation22 and decreased occurrence of pneumothorax23 24 as a result of enhanced lung compliance after surfactant treatment. Changes in cerebral blood flow occur in both pneumothorax and intraventricular haemorrhage and merit further investigation.
Although our study design allowed for random allocation of babies into treatment and control groups, there were more treated babies born by caesarean section for severe placental abruption and more control babies born by breech delivery. These differences were not significant and probably not clinically important as babies in both groups had similar Apgar scores and need for intubation at birth. We also believe that babies in both groups were at similar risk of developing intraventricular haemorrhage and indeed at time of entry into the study similar numbers had grade I and II haemorrhages.
It has been suggested that grade I (or subependymal) and II haemorrhages have a good prognosis and that only grade III and IV haemorrhages are associated with long term neurological handicaps. 25 Some reports, however, show that up to 50% of infants with grade II haemorrhages will have mild neurological abnormalities.26 For this reason we believe that our babies treated with surfactant should have an improved long term developmental prognosis when compared with our control infants who were treated with conventional mechanical ventilation. Follow up studies are under way.
Our rates of pneumothorax (80%) and mortality (60%) in the control group were high but they further emphasised the severity of the respiratory distress syndrome in our patients. None of our five control babies of less than 1200 g weight survived.
During the study 76 babies weighing <1200 g and without major congenital abnormality had mechanical ventilation for respiratory distress syndrome but only 12 were ill enough to be entered into the trial. Only 11 of the 64 non-study babies died (17%), which compares favourably with the mortality of babies in the treatment group (29%). Our incidence of pneumothorax in a consecutive series of 433 babies treated with mechanical ventilation is 15%. 27 Greenough et al have reported an incidence of pneumothorax of 100% in babies making expiratory efforts against the ventilator and suggested that use of muscle relaxants prevented this complication.28 Twelve (80%) of our control babies, however, were given muscle relaxants or sedation with diazepam before pneumothorax occurred. If muscle relaxants were used they were always started before the age of 48 hours and most of the pneumothoraces occurred after 48 hours. We had no clinical or radiological evidence of pneumothorax before starting muscle relaxants in any baby in the study.
Not all babies showed sustained improvement after surfactant treatment and all continued to need intensive care and mechanical ventilation for some time. In one study infants needed repeated treatments to sustain effects.8 Prophylaxis may be the best method of further reducing the incidence of intraventricular haemorrhage and other complications. The infiltrates observed radiologically in some patients after surfactant replacement can mimic pneumonia and may be due to a form of interstitial reaction to the exogenous material29; we found no evidence of bacterial infection in these babies.
Long term studies on infants treated with surfactant are few30 31 
